CLINICAL IMPROVEMENT OF A PATIENT WITH SEVERE PSORIASIS FOLLOWING CD4ANTIBODY ADMINISTRATION DESPITE A BLOCKING MINTS ANTIBODY HOST RESPONSE

The host antibody response is responsible for interference with the cl inical effectiveness of is usually (mAbs). The patient's immunity agai nst therapeutic mAbs is usually monitored and the presence to further administration. We previously reported in a pilot study that administr ation of a murine CD4 mAb, B-F5, induced a rapid, clinical improvement in patients with severe psoriasis. In the present study, we report th e case of a received two additional short-term administrations (2 days ) of B-F5. Despite the presence of blocking anti-B-FS antibodies befor e the last course, B-F5 infusion was well-tolerated and resulted in cl inical improvement. Thus, short-term administration of CD4 mAb could b e clinically effective despite the presence of HAMAs. of HAMAs. This o bservation suggests that assays for blocking antibodies should be re-e valuated with respect to their clinical relevance.